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Abstract: To evaluate the diagnostic route of pheochromocytoma
(PHEO) in a patient under dopaminergic treatment.
A 70-year-old man with Parkinsonism and under treatment with
levodopa and carbidopa came to our observation for evaluation of
arterial hypertension and right adrenal mass discovered incidentally.
To evaluate adrenal hormone levels we performed a dexamethasone
suppression test, plasma aldosterone levels and 24-hr urinary meta-
nephrine, which revealed elevated levels of catecholamines metaboli-
ties. 123-I-metaiodobenzylguanidine SPECT scintiscan revealed raised
activity within the right adrenal gland concordant with the mass. The
diagnosis of PHEO was posed and an elective laparoscopic adrenalect-
omy was performed; histopathological examination confirmed the
PHEO diagnosis.
Recently the coexistence of PHEO and Parkinsonism is a very rare
association of diseases, with only 3 cases reported in literature. In this
article, another case is reported and diagnostic procedures are discussed.
(Medicine 94(42):e1855)
Abbreviations: PHEO = pheochromocytoma, MRI = magnetic
resonance imaging.
INTRODUCTION
P heochromocytoma (PHEO) and paraganglioma (PGL) areneural-crest derived neoplasms, primarily found in the
adrenal gland with a prevalence of 0.1% to 0.6% in patients
affected by hypertension.1 Tumors of adrenal medulla predo-
minantly secrete norepinephrine over epinephrine, instead adre-
nal medulla normally secretes 80% of epinephrine.
Hypertension, either paroxysmal or sustained, is the most
consistent finding in neoplasms, and the classical triad ofcci, MD, Piernatal
and Claudio Letizia, MD
oedema, arrhythmias, or intrachranial hemorrhage. The coex-
istence of PHEO and Parkinson’s disease or Parkinsonism is
very rare, with only 3 cases reported in literature.3–5
CASE REPORT
A 70-year-old man with history of Parkinsonism and
diabetes mellitus presented to the Specialized Center of Sec-
ondary Hypertension, University of Rome ‘‘La Sapienza,’’
Rome, Italy for an evaluation of hypertension and an adrenal
incidentaloma that was detected on abdomen ultrasonography
(US) and confirmed by magnetic resonance imaging (MRI)
(3 2 cm round mass with the presence of necrotic areas;
Figure 1A). The patient signed an informed consent to partici-
pate in this case report.
At the age of 67 years the patient begun to exhibit gait
deficits and bradykinesia of the left lower limb, followed by
stiffness of the trunk and amimica facies and limitation in
upward gaze. An 123-I-FP-CIT (DAT-SCAN)-SPECT showed
a reduction in the physiological concentration in brain presyn-
aptic dopamine transporters with consequent reduction of the
striatal structures. The clinical features appeared compatible
with the diagnosis of Parkinsonism associated with pseudobul-
bar syndrome. Levodopa and benserazide therapy was started,
subsequently replaced with levodopa and carbidopa at a dose of
750mg per daily. After starting treatment with levodopa and
carbidopa, the patient had a marked improvement in symptoms.
He did not report any complaints of episodic headaches, palpi-
tations, sweating, and chest pain. On examination, patient’s
pulse rate was 67 beats min1, blood pressure (BP) was 160/
100mmHg, with postural drop (140/80mmHg). His height was
181 cm, and his weight was 75 kg, with a body mass index of
22.8 kg m2. No cardiac murmurs or abdominal bruits were
revealed. His average 24-hr-ambulatory-BP (ABPM) was 130/
90mm Hg, with ‘‘nondipping’’ profile. The ECG was normal
and mild left ventricular concentric remodeling was showed by
an echocardiography.
The patient was under treatment with irbesartan, nebivolol,
metformin, levodopa, and carbidopa. Routine blood tests were
normal except for fasting blood glucose (138mg dL1; normal
range 70–100mg dL1). After replacing nebivolol and irbe-
sartan with nifedipine (60mg per daily) and doxazosin (8mg
per daily) BP decreased to normal values (135/85mm Hg), and
biochemical tests to determine functional hormone secretion
were performed. Investigation for adrenal hormones, including
low-dose dexamethasone suppression test, plasma aldosterone
levels were normal, while 2 repeated 24-hr-urinary metane-
phrines measurements were elevated (721 and 782mg/24 hr;
normal range 20–345mg/24 hr; Table 1).probability of adrenal PHEO, a 123-I-
ine (123-I-MIBG) SPECT scintiscan
Bq of 123 I-MIBG was i.v. administered
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FIGURE 1. (A) Magnetic resonance imaging (MRI): mass in the
right adrenal gland (32 cm) with the presence of necrotic areas.
(B) Thorax scintiscan with 123-I metaiodio benzilguanidine (123-
I-MIBG) showed a severely reduced MIBG cardiac uptake, with a
heart to mediastinum (HM) ratio of 1.38. (C) Scintiscan with 123-I
metaiodio benzilguanidine (123-I-MIBG) shows raised activity
within the right adrenal gland.
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2 | www.md-journal.comand planar images of thorax were obtained at 20min and 4 hr,
while images of abdomen were obtained at 4 and 24 hr. Thorax
scan showed a severely reduced MIBG cardiac uptake, with a
heart to mediastinum (HM) ratio of 1.38 (HM cut off: 2), highly
suggestive of a Parkinson’s disease (Fig. 1B); whereas,
abdomen scan revealed raised activity within the right adrenal
gland, concordant with the mass (Fig. 1C). A surgical consult
was requested, and the patient, now diagnosed with PHEO, was
to undergo a surgical resection; however, the surgery was
postponed, and the patient was prescribed with 4mg of dox-
azosin twice a day, followed by 5mg of nebivolol daily after
testing for the adequacy of the a-blockade in order to prevent
paroxysmal increases of BP during surgery. One month later,
with a BP of 135/80mm Hg, the patient underwent a laparo-
scopic tumor resection. The histopathological examination
confirmed the diagnosis of PHEO. The patient has been in
regular follow-up for the 12 months, and in treatment with
levodopa and carbidopa in addition to doxazosin (4mg per
daily). During the follow-up adrenal hormone tests were run
(Table 1). Office and ABPM showed optimal control of BP
(average systolic and diastolic BP 125/75mm Hg), and labora-
tory analysis showed normal values of fasting glicemia (89mg
dL1) without metformin treatment.
DISCUSSION
Since the introduction of imaging techniques in medical
practice, abnormalities of unknown clinical significance were
found more often. One of these abnormalities is the adrenal
incidentaloma.6 Pathology of adrenal incidentaloma may vary
from simple benign cyst or lipoma to adrenal carcinoma. The
differential diagnosis of the adrenal mass includes several
conditions, such as adenoma, myelolipoma, cyst, lipoma,
PHEO, hyperplasia, adrenal cancer, and metastatic cancer.7
In order to differentiate the adrenal mass detected on abdominal
imaging studies, patients should always be evaluated with
hormonal tests.8,9 This hormonal evaluation can be difficult
with patients with comorbidities, or with patients who are
prescribed with interfering medications.
In this article, we discuss the case of PHEO in Parkinso-
nian patient, in treatment with dopaminergic medications, that
presented with an adrenal incidentaloma. Currently only 3 cases
have been reported in literature.3–5 Our patient represented the
fourth case, and the first one in Italy.
The first case reported by Metha et al3 is a 59-year-old
American man with a 7-year history of Parkinson’s disease,
presented episodes of sudden severe headaches with neck pain,
tachycardia, sweating, and paleness associated with marked
elevation of BP. These symptoms suggested a condition of
hypercathecolaminism, and even though further tests revealed
normal values of plasma and urinary metanephrines, an 123-I-
MIBG-single photon CT (SPECT) was positive for increased
uptake in the left adrenal region concordant with the nodule
showed in the MRI scan. The histopathological examination,
after laparoscopic adrenalectomy, revealed an adrenal
medullary hyperplasia.
The second case reported by Collier et al4 is about a 63-
year-old American man, with a 5-year history of Parkinson’s
disease and a left adrenal incidentaloma. The urinary metabo-
lities of catecholamines were elevated, and 123-I-MIBG con-
firmed an increased activity within the left adrenal gland.
Medicine  Volume 94, Number 42, October 2015Histological examination following laparoscopic surgical exci-
sion showed the presence of a composite PHEO/PGL/gang-
lioneuroma.
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TABLE 1. Endocrinological data
At Diagnosis After Surgery (1 yr) Range
Serum
Plasma renin activity (PRA) 0.31 0.5 0.2–2.7 ng mL1 hr1
Plasma aldosterone (PAC) 14.04 10.45 3.0–16.0 ng dL1
Plasma cortisol 13 16.5 4.5–21.0mg dL1
Plasma ACTH 20 23 10–90 pg mL1
PAC/PRA ratio 36.4 20.9 <40 ng mL1 hr1:ng dL1
Urine
Free cortisol (UFC) 155 143.4 38–200mg/24 hr
Aldosterone (UAC) 20 22.5 2.84–34.00mg/24 hr
Metanephrines 721; 782 108 20–345mg/24 hr
Dexamethasone suppression test (1mg) at diagnosis
Plasma cortisol 4 <5mg dL1
ncen
Medicine  Volume 94, Number 42, October 2015 Parkinson’s Disease and PheochromocytomaThe third case reported by Shimodaira et al5 is about a 75-
year-old Japanese man, affected by Parkinson’s disease and
paroxysmal hypertension associated with vague abdominal
symptoms and right adrenal mass showed during abdominal
US. Urine analysis revealed elevated levels of catecholamines
and their metabolites, and 123-I-MIBG scintigraphy showed
increased uptake in the right adrenal gland concordant with
computed tomography (CT). After laparoscopic adrenalectomy,
histopathological examination analysis of the mass confirmed
the diagnosis of PHEO.
Parkinson’s disease is a chronic neurodegenerative dis-
order characterized by dopaminergic dysfunction and disturb-
ances in neurotransmitter system with motor system disorders
including tremor, rigidity, slowness of movement, and impaired
balance or coordination. Primary treatment involves oral dopa-
minergic drugs such as levodopa. Levodopa is converted per-
ipherally to other cathecolamines, such as norepinephrine,
epinephrine, and their metabolites, and medications containing
levodopa may cause false-positive results in endocrine testing
for PHEO.10
The clinical presentation and biohumoral markers of
PHEO depend on the capacity of the neoplasm to synthesize,
metabolize, and release catecholamines and their metabolites
into circulation. Initial biochemical tests for PHEO, recom-
mended by Clinical Guidelines Subcommittee of Endocrine
Society,11 should include measurements of plasma-free meta-
nephrines or urinary fractionated metanephrines.
In fact, traditional biochemical tests, including measure-
ments of urine and plasma cathecolamines, and urinary vanil-
mandelic acid, may be unreliable because catecholamine
secretion in PHEO is often episodic or even negligible in
asymptomatic patients. The higher diagnostic accuracy of
metanephrines can be attributed to continuous intratumoral
production and secretion of metanephrines into circulatory
compartment.10 Particularly, the measurements of urine meta-
nephrines by mass spectrometry provide excellent sensitivity
(97%) and specificity (91%) for diagnosis of PHEO.
Several factors have to be taken into account in order to
attain a correct interpretation of biochemical test results. Pre-
analytical factors may affect the results, such as exercise,
posture, food, stress, and medications; these factors may alter
ACTH
ACTH¼ adrenocorticotropic hormone, UAC¼ urinary aldosteron coproduction or disposition of catecholamines and their metab-
olites. Particularly, some drugs (acetaminophen, labetalol, bus-
pirone, mesalazine, sulfasalazine, tricyclic antidepressants, and
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.levodopa) can interfere analytically or pharmacodynamically
with measurements of plasma and urinary catecholamines and
metabolites, which may result in false-positive test results.11,12
Particularly, levodopa causes falsely elevated urine normeta-
nephrine, and it can also cause mildly raised values of urine
metanephrines.12 Regarding our patient, the dopaminergic
medications (levodopa and carbidopa) may have interfered in
the measurement of free urinary metanephrines; as it was
impossible to discontinue these medications, we performed
determination of urinary metanephrines only.
Another important data showed in these case report (com-
prised our case) were that in all Parkinsonian patients with
suspected diagnosis of PHEO and in treatment with dopamin-
ergic drugs the 123-I-MIBG was performed. The MIBG scinti-
graphy is based on evidence that norepinephrine and MIBG
have the same mechanisms for uptake, storage, and release.13
Radiolabeled I-MIBG demonstrate high uptake both in
normal sympathetically innervated tissues, such as the heart and
salivary glands, and in tumors that express the neurohormone
transporters, specifically those of neural crest and neuroendo-
crine origin.14 Currently, 123-I-MIBG is considered the gold
standard in diagnosing these tumors. Particularly, 123-I-MIBG
scintigraphy is used as a diagnostic tool for the detection of
PHEO. The sensitivity of 123-I-MIBG scintigraphy in PHEO is
reported to be 95%, whereas the specificity is 80% to 90%.15
However, tumors smaller than 1.5 cm in diameter and with
extensive necrosis or hemorrhage may yield false-negative
results due to poor uptake of the tracer. Only limited reports
of false-positive uptake in other lesions have been published,16
and 1 major cause of false-positive findings is urinary tract
retention, since the reagent is excreted in the urine.17
Recently, Jacobson et al,15 in a recent meta-analysis of 123-
MIBG, concluded that ‘‘although results in clinical practice will
likely be a few percentages lower, the long history of successful
use of this technique and the recent prospective clinical trial
support that continued utility of 123-I-MIBG imaging in the
diagnosis and management of patients with PHEO.’’
Another finding observed in our Parkinsonian patient
during 123I-MIBG (SPECT) scan was the reduced cardiac
uptake of the ligand, which was consistent with the postgangli-
onic sympathetic denervation which is frequent in Parkinson’s
9 <50% of baseline
tration, UFC¼ urinary free cortisol.disease. In fact, in recent years, cardiac scintigraphy withMIBG
labeled with iodine (123-I) have been used in Parkinson’s
disease for evaluating noradrenergic activity of myocardium.
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This method provides a functional analysis of the sympathetic
postganglionic pathway to evaluate ‘‘in vivo’’ the noradren-
ergic neurotransmission of the heart.18
In conclusion, a feature of Parkinson’s disease appears to
be an inverse correlation with all types of cancer excluding
malignant melanoma. Interestingly, the melanocytes and the
cells of the PHEO derived both from the neural crest. Moreover,
these 2 types of cells and neurons of the substantia nigra,
ascribed to the pathogenesis of Parkinson’s disease, are all
Petramala et alpigmented cells.19 This is the only association in contrast to
the finding that neurodegenerative diseases have a lower risk of
developing neoplasms.20,21
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